登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C29H53NO5
化学文摘社编号:
分子量:
495.73
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
InChI
1S/C29H53NO5/c1-5-7-9-11-12-13-14-15-16-18-24(34-29(33)26(30-22-31)20-23(3)4)21-27-25(28(32)35-27)19-17-10-8-6-2/h22-27H,5-21H2,1-4H3,(H,30,31)/t24-,25-,26-,27-/m0/s1
SMILES string
CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O
InChI key
AHLBNYSZXLDEJQ-FWEHEUNISA-N
grade
pharmaceutical primary standard
API family
orlistat
manufacturer/tradename
USP
application(s)
pharmaceutical (small molecule)
format
neat
Gene Information
human ... LIPF(8513), PNLIP(5406)
正在寻找类似产品? 访问 产品对比指南
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Orlistat USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.
Biochem/physiol Actions
奥利司他用于肥胖症研究，是一种胰脂肪酶抑制剂，在胃肠道局部起作用以抑制脂肪酶。
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Other Notes
溶液不完全澄清，小颗粒可能仍然悬浮。
Sales restrictions may apply.
存储类别
11 - Combustible Solids
flash_point_f
Not applicable
flash_point_c
Not applicable
György Paragh et al.
Orvosi hetilap, 146(11), 493-498 (2005-04-09)
The overweight and obesity represent severe problems for the health management system of developed countries. In the evolution of obesity, beside genetic background, the environmental factors also play important roles. In the daily routine, the majority of obese patients need
James W Anderson
Expert opinion on pharmacotherapy, 8(11), 1733-1742 (2007-08-10)
Orlistat, in the 60-mg over-the-counter dose, was recently approved by the FDA. This lipase inhibitor blocks absorption of ~25% of ingested fat and has ~85% of the efficacy of the 120-mg dose for weight loss. Over 16 weeks weight loss
Sheridan Henness et al.
Drugs, 66(12), 1625-1656 (2006-09-08)
Orlistat (Xenical) is a reversible inhibitor of gastric and pancreatic lipases. In conjunction with a hypocaloric diet and moderate exercise, orlistat is an effective drug for use in the management of obesity in adults with or without comorbidities. Recent data
Walmir Coutinho
Arquivos brasileiros de endocrinologia e metabologia, 53(2), 262-270 (2009-05-26)
Ancillary therapies for weight management, consisting mainly of diet and exercise programs that incorporate variable levels of lifestyle modification techniques, are frequently ineffective to achieve clinically meaningful weight loss and maintenance. Although pharmacological treatment of obesity is widely used in
D N Kiortsis et al.
Diabetes & metabolism, 31(1), 15-22 (2005-04-02)
Orlistat is an antiobesity drug with a well documented efficacy in weight reduction and weight maintenance. Weight reduction with orlistat has been associated with a favourable effect on obesity-related cardiovascular risk factors. Orlistat treatment is associated with a reduction in
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持